FindTrial
Sign In

PNEUMOVAX™23

BIOLOGICAL7 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Pneumococcal InfectionPneumococcal InfectionsPneumonia, Pneumococcal

Phase 1

A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)
CompletedNCT04168190
Merck Sharp & Dohme LLCPneumonia, Pneumococcal
Start: 2019-12-06End: 2021-07-12Updated: 2022-09-16
Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)
CompletedNCT04665050
Merck Sharp & Dohme LLCPneumococcal Infection
Start: 2021-02-04End: 2021-04-06Updated: 2023-10-04

Phase 3

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)
CompletedNCT03480802
Merck Sharp & Dohme LLCPneumococcal Infections
Start: 2018-07-06End: 2020-01-17Updated: 2022-05-05
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)
CompletedNCT03480763
Merck Sharp & Dohme LLCPneumococcal Infections
Start: 2018-06-22End: 2019-12-23Updated: 2021-11-02
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)
CompletedNCT03547167
Merck Sharp & Dohme LLCPneumococcal Infections
Start: 2018-07-16End: 2020-01-20Updated: 2021-01-15
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)
CompletedNCT03565900
Merck Sharp & Dohme LLCPneumococcal Infections
Start: 2018-09-12End: 2021-11-04Updated: 2023-07-28
Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)
CompletedNCT03921424
Merck Sharp & Dohme LLCPneumococcal Infections
Start: 2019-11-05End: 2021-05-03Updated: 2023-06-07

Related Papers

Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18-49 Years of Age Enrolled at Center for Indigenous Health Sites.
2025-12-19
The impact of pneumococcal vaccination and nasopharyngeal colonization on the performance of a serotype-specific urine antigen detection (SSUAD) assay
Vaccine2025-08-011 citations
Immune persistence of a single dose of 23-valent pneumococcal polysaccharide vaccine: A 6-year follow-up
Human Vaccines & Immunotherapeutics2025-06-192 citations
A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM)
Clinical Infectious Diseases2023-06-2013 citations
A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV
AIDS2023-03-173 citations
Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.
2022-09-1560 citations
Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18–49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY)
Open Forum Infectious Diseases2021-12-1816 citations
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV
AIDS2021-11-0925 citations
Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH).
2021-09-0431 citations